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Platelet-derived growth factor (PDGF) and its cognate receptor are widely expressed on melanomas. Coexpression
of the growth factor and receptor suggests their role in autocrine or paracrine growth mechanisms. Imatinib
mesylate was previously reported to have speciﬁc activity in inhibiting select tyrosine kinase receptors, including
PDGF and c-Kit. Melanoma cells express abundant levels of the PDGF receptor (PDGFR). Nevertheless, c-Kit
expression is progressively lost as the cells take on a more highly metastatic phenotype. To investigate the
potential of imatinib mesylate as a therapy for melanoma, we studied its effect on the growth of melanoma cells
using an in vivo mouse model. Melanoma cells with high malignant potential (PDGFR-positive, c-Kit-negative) or
low malignant potential (PDGFR-positive, c-Kit-positive) were injected subcutaneously into athymic nude mice.
Mice were treated with imatinib mesylate (100 mg/kg three times weekly) or with phosphate-buffered saline for 4 to 6
wk. PDGFR-a and -b were expressed on all melanoma cell lines tested. The level of PDGFR expression correlated
with the metastatic potential of the melanoma cells: higher levels of PDGFR-a were expressed on cells with higher
metastatic potential, and higher levels of PDGFR-b were expressed on cells with lower metastatic potential. There
was no signiﬁcant difference in tumor size between treated and control mice. Immunohistochemical studies
demonstrated inhibition of PDGFR phosphorylation on the tumors from mice treated with imatinib mesylate but not
from control mice, suggesting that the receptors were functional and that the concentration of drug used was
appropriate. Our data demonstrated that imatinib mesylate blocked both PDGFR-a and PDGFR-b in vivo. It did not,
however, affect the growth of melanoma cells expressing PDGFR, regardless of whether the cells expressed c-Kit.
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In the United States, melanoma is the eighth most prevalent
cancer (Wingo et al, 1995). Melanoma is predominantly
diagnosed in the third and fourth decades of life; thus, the
disease is a significant public health concern. Nevertheless,
in women 25 to 29 y old, melanoma is the most common
cancer, and in women between 30 and 34 y old, it is the
second most common type of malignancy after breast
cancer (Brochez and Naeyaert, 2000). In 1998, the age-
adjusted incidence of invasive cutaneous melanoma was
18.3 in 100,000 men and 13.0 in 100,000 women in the
United States (Jones et al, 1999). Melanoma is largely
curable if identified at any early stage. Unfortunately,
patients with locally advanced or metastatic disease are
left with few medical treatment options. Therefore, there is a
growing need to investigate novel agents that are both
efficacious and minimally toxic.
In recent years, increasing attention has been directed at
small molecules that specifically inhibit tyrosine kinase
receptors, many of which are dependent on growth factors
that act by autocrine or paracrine mechanisms (Baserga,
1994). The development of compounds that selectively
inhibit growth-factor-signaling loops may present new
treatment strategies for the management of several tumors.
One such compound is imatinib mesylate (Gleevec,
formerly known as STI571 and CGP57148B, Novartis
Pharmaceuticals, Basel, Switzerland). Imatinib mesylate
was developed as an ATP-competitive inhibitor of ABL
tyrosine kinase (Druker et al, 1996). This molecule also
inhibits other tyrosine kinases, including platelet-derived
growth factor receptor (PDGFR) and c-Kit, at concentra-
tions required to inhibit Bcr-ABL (Carroll et al, 1997).
Recently, imatinib mesylate has been approved by the
United States Food and Drug Administration for the
treatment of c-Kit-positive gastrointestinal stromal tumors
and Philadelphia-chromosome-positive chronic myelogen-
ous leukemia.
Abbreviations: PBS, phosphate-buffered saline; PDGF, platelet-
derived growth factor; PDGFR, PDGF receptor.
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PDGF is a potent mitogen for cells of mesenchymal
origin. Acting through its cognate receptor, PDGF has been
shown to affect cellular proliferation, chemotaxis, and cell
survival (Heldin and Westermark, 1999). Therefore, inhibition
of PDGFR activation may inhibit the growth of several
PDGFR-expressing tumors. Indeed, the effect of imatinib
mesylate on in vivo tumor growth and PDGFR signaling has
been studied in various types of tumors (Tomasson et al,
1999; Sjoblom et al, 2001; McGary et al, 2002; Uehara et al,
2003; Zhang et al, 2003). Several studies have confirmed
the expression of PDGF and its cognate receptors on
melanoma cells, suggesting that inhibition of these recep-
tors may affect the growth of melanoma cells in vivo
(Westphal et al, 2000; Barnhill et al, 1996; Kubo et al, 1998).
The expression of a second target for imatinib mesylate,
c-Kit, has been extensively studied in melanoma. Both c-Kit
and its ligand play important roles in the normal growth and
differentiation of melanoblasts. As melanoma cells acquire a
more malignant phenotype, as determined by the extent of
local tumor growth, invasion, and the ability to metastasize,
c-Kit expression is downregulated (Lassam and Bickford,
1992; Natali et al, 1992; Zakut et al, 1993). Indeed, the
majority of highly metastatic human melanomas do not
express detectable levels of the c-Kit receptor (Lassam and
Bickford, 1992; Natali et al, 1992; Zakut et al, 1993). We
have previously shown that enforced c-Kit expression
significantly inhibits melanoma growth in vivo and that
exposure of c-Kit-positive cells to stem cell factor (SCF) led
to apoptosis of these cells (Huang et al, 1996). These
findings raise the question as to the whether malignant
transformation of melanocytes may be associated with
changes in c-Kit expression. Several studies have shown
that imatinib mesylate inhibits tumor growth of several
nonmelanoma c-Kit-positive tumor types (Krystal et al,
2000; Merchant et al, 2002; Vitali et al, 2003). Nevertheless,
our prior studies suggest that functional blockade of c-Kit
by imatinib mesylate may possibly promote the growth of c-
Kit-positive melanoma cells with low metastatic potential.
Furthermore, treatment with imatinib mesylate could poten-
tially select for the more aggressive c-Kit-negative melano-
ma cells in vivo.
The purpose of this study was to determine whether
imatinib mesylate would affect the growth of melanoma
xenografts in vivo and whether the effect, if any, was
dependent on the level of PDGFR and c-Kit expressed on
those cells.
Results
Expression of PDGFR-a and -b on human melanoma
cells correlates with their metastatic potential Specific
tyrosine kinase receptors are targets for imatinib mesylate.
For example, imatinib mesylate inhibits PDGFR at con-
centrations similar to those that inhibit Bcr-Abl (Carroll
et al, 1997). A prior study demonstrated the presence of
PDGFR-a but not PDGFR-b on human melanoma speci-
mens (Barnhill et al, 1996). To determine whether human
melanoma cells express adequate levels of PDGFR on their
cell surface, we determined their expression by western
blotting with primary antibodies specific for either PDGFR-a
or PDGFR-b. PDGFR-a was expressed on all five human
melanoma cell lines tested. Nevertheless, the level of
expression was significantly greater on melanoma cell lines
with high metastatic potential (A375SM, TXM-13, and WM-
266-4) than it was on those with low metastatic potential
(SB-2 and MeWo; Fig 1). Similarly, PDGFR-b was expressed
on all five cell lines tested; however, unlike PDGFR-a,
PDGFR-b expression was significantly greater on melano-
ma cell lines with low metastatic potential (SB-2 and MeWo)
than it was on those with high metastatic potential
(A375SM, TXM-13, and WM-266–4; Fig 1). We have
previously shown that c-Kit is expressed on the nonmeta-
static cell lines SB-2 and MeWo but its expression is lost on
the highly metastatic A375SM, WM-266-4, and TXM-13
cells (Huang et al, 1996, 1998).
Imatinib mesylate does not affect the growth of A375SM
or MeWo human melanomas in vivo To study the effect of
imatinib mesylate on melanoma growth in vivo, either
A375SM or MeWo melanoma cells were orthotopically
introduced into nude mice by subcutaneous injection. Three
days after injection, mice were randomized to the control
arm (untreated) or the imatinib mesylate treatment arm.
Tumor growth was assessed in both groups twice weekly.
We have previously shown that c-Kit expression is inversely
correlated with the metastatic potential of human melano-
mas (Huang et al, 1996, 1998). At concentrations required
for inhibition of Bcr-Abl, imatinib mesylate also inhibits c-Kit
(Carroll et al, 1997). Therefore, it is plausible that in c-Kit-
positive melanomas with low metastatic potential (e.g.,
MeWo), treatment with imatinib mesylate could promote
tumorigenicity through functional blockade of c-Kit. This
is of particular importance because imatinib mesylate is
currently being investigated in several human clinical trials.
Both MeWo and A375SM melanoma cell lines express
PDGFR. The former express higher levels of PDGFR-a, and
the latter, higher levels of PDGFR-b (Fig 1). In addition to
PDGFR, MeWo melanoma cells express c-Kit, whereas
Figure1
Western blot analysis for the expression of PDGFR-a and PDGFR-b
on human melanoma cell lines. Equal loading of gels was determined
by actin expression. Total cell lysates from MG-63 osteosarcoma cells
(6 mg) and 3T3 fibroblast cells (20 mg) were used as positive controls for
PDGFR expression. The level of PDGFR-a and PDGFR-b expression
was determined after loading 30 mg of total protein lysates from various
human melanoma cells: WM-266-4, TXM-13, A375SM, MeWo, and
SB-2.
EFFECT OF IMATINIB MESYLATE ON MELANOMA TUMORIGENICITY 401122 : 2 FEBRUARY 2004
A375SM melanoma cells do not (Huang et al, 1996, 1998).
To determine whether imatinib mesylate affects the growth
of PDGFR-positive and c-Kit-negative or -positive melano-
mas, xenografts were established in nude mice by
subcutaneous injection with A375SM or MeWo cells (day
0). Mice bearing melanoma xenografts were randomly
allocated to one of two treatments: imatinib mesylate or
PBS (control group). Tumor growth was periodically
determined. After 31 d of treatment, there was no significant
difference in the size of tumors (A375SM) in mice treated
with imatinib mesylate and in those treated with PBS (Fig
2A). Similarly, after 50 d of treatment, there was no
significant difference in the size of tumors (MeWo) in mice
treated with imatinib mesylate and in mice treated with PBS
(Fig 2B). Taken together, these data demonstrate that
imatinib mesylate had no effect on the growth of PDGFR-
positive human melanoma xenografts, regardless of c-Kit
expression.
Imatinib mesylate inhibits PDGFR-a and -b phosphor-
ylation in melanoma xenografts To determine whether
imatinib mesylate was biologically active in mice bearing
human melanoma xenografts, PDGFR phosphorylation was
determined by immunohistochemistry on frozen sections
derived from melanoma xenografts. Receptor phosphoryla-
tion was determined by immunohistochemistry with primary
antibodies specific for epitopes corresponding to the short
amino acid sequences containing phosphorylated Tyr-720
Figure 2
Effect of imatinib mesylate on the
growth of melanoma xenografts in vivo.
Nine-wk-old nude mice were injected
subcutaneously with 1  106 MeWo or
A375SM cells and treated with imatinib
mesylate (100 mg/kg) or PBS three times
weekly for 4 to 6 weeks. Tumor growth
was periodically determined. (A) There
was no significant difference in the
growth of A375SM (PDGFR-positive,
c-Kit-negative) xenografts among mice
treated with imatinib mesylate or control
at any point measured. (B) There was no
significant difference in the growth of
MeWo (PDGFR-positive, c-Kit-positive)
xenografts among mice treated with
imatinib mesylate or control at any point
measured. At each interval, mean tumor
volume was compared between the
treated and control mice with a two-
tailed Student’s t test. The level of
significance was set at po0.05.
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and Tyr-1021 of PDGFR-a and PDGFR-b, respectively. Both
PDGFR-a and PDGFR-b were expressed on A375SM
melanoma xenografts in both imatinib mesylate- and
control-treated mice (Fig 3), suggesting that imatinib
mesylate had no effect on the level of PDGFR expression.
Nevertheless, in mice treated with imatinib mesylate, there
was a significant reduction in PDGFR-a and PDGFR-b
phosphorylation. There was no effect on PDGFR phosphor-
ylation in control mice treated with PBS. These data indicate
that in the treatment group, 100 mg per kg imatinib
mesylate provided adequate in vivo plasma levels to inhibit
both PDGFR-a and PDGFR-b phosphorylation. These
findings demonstrate that the PDGFR on the melanoma
cells tested were functional and that the concentration and
dosing schedule of imatinib mesylate were appropriate for
our in vivo studies.
Discussion
Our in vitro studies demonstrated that both PDGFR-a and
PDGFR-b were widely expressed on all melanoma cell lines
tested. A previous study had shown that only PDGFR-a was
expressed in vivo on human primary and metastatic
melanoma specimens (Barnhill et al, 1996). Possibly, our
ability to detect PDGFR-b resulted from our using a different
primary antibody with a different binding affinity. Further-
more, it is possible that in vivo, PDGFR-b is downregulated
through epigenetic, transcriptional, or posttranscriptional
mechanisms. Nevertheless, we also studied the expression
of PDGFR-a and PDGFR-b on human primary and meta-
static melanoma specimens. Using the same primary
antibodies that had been used previously to detect
PDGFR-a and PDGFR-b expression on melanoma cell lines
in vitro, we were also able to detect expression of both
PDGFR-a and PDGFR-b on the majority of human speci-
mens tested (M. Bar-Eli, unpublished data).
We also showed that the level of PDGFR correlates with
the metastatic potential of the melanoma cell lines tested.
The level of PDGFR-a expression was greater on melanoma
cells with high metastatic potential, whereas the level of
PDGFR-b expression was greater on melanoma cells with
low metastatic potential. No correlation has been estab-
lished between PDGFR-a expression and the V599E BRAF
Figure 3
Imatinib mesylate inhibits PDGFR-a
and PDGFR-b phosphorylation in mel-
anoma xenografts. Immunohistochem-
istry was performed on frozen sections
obtained from A375SM xenografts har-
vested from nude mice. The mice were
treated with either imatinib mesylate
(treatment arm) or PBS (control arm).
PDGFR-a and PDGFR-b phosphoryla-
tion was determined using primary
antibodies specific for epitopes corre-
sponding to phosphorylated Tyr-720 and
Tyr-1021, respectively. Cells taken from
treated and untreated mice are pre-
sented with the same magnification.
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mutant. For example, we detected V599E mutation in the
WM2664 cells but not in TXM-13 (data not shown).
Nevertheless, both cell lines express high levels of
PDGFR-a. As the malignant phenotype of melanoma cells
changes from the noninvasive radial growth phase to the
vertical growth phase, which has high metastatic potential,
so does the repertoire of the molecules expressed on the
cells’ surface. We have previously shown that expression of
the cellular adhesion molecule MCAM/MUC18 is increased
in melanoma cells with high metastatic potential (Xie et al,
1997). Another study demonstrated that the expression of
the tyrosine kinase receptor c-Kit is downregulated in
melanoma cells with high metastatic potential (Natali et al,
1992). Nevertheless, to the best of our knowledge, we are
unaware of any studies that have shown a correlation
between PDGFR expression and the metastatic potential of
melanoma cells in vitro. We are currently investigating
whether changes in PDGFR expression may play a role in
the malignant transformation of melanocytes.
Although many PDGFR antagonists exist, we chose to
study the effect of imatinib mesylate on the growth of
melanoma xenografts. In addition to studying its effect on
PDGFR-positive melanoma xenografts, we also studied its
effect on melanoma xenografts that were established from
c-Kit-positive and -negative melanoma cell lines. Our prior
studies suggested that c-Kit expression may inhibit mela-
noma tumorigenicity (Huang et al, 1996, 1998). Therefore,
functional blockade of c-Kit-positive melanoma cells could
possibly promote tumor growth in vivo. This is of particular
importance given the fact that imatinib mesylate is currently
being investigated in human clinical trials for the treatment
of melanoma.
Our data demonstrate that in mice bearing PDGFR-
positive, c-Kit-negative xenografts established from the
A375SM melanoma cell line, imatinib mesylate had no
effect on tumor growth. We further found through immuno-
histochemical studies that both PDGFR-a and PDGFR-b
phosphorylation was inhibited in those mice treated with
imatinib mesylate. These findings suggest that the concen-
tration of imatinib mesylate used was appropriate and that
the PDGFR were functional. Redundancies in growth factor
loops have been described (Benini et al, 1999) and may
partly explain why inhibition of PDGFR activation had no
effect on tumor growth. Similarly, in mice bearing PDGFR-
positive, c-Kit-positive xenografts established from the
MeWo melanoma cell line, imatinib mesylate had no effect
on tumor growth. This demonstrates that functional block-
ade of c-Kit by imatinib mesylate is not sufficient to promote
tumor growth in mice bearing xenografts established from
c-Kit-positive melanoma cells that exhibit low metastatic
potential. This finding suggests that the transformation from
melanoma cells with low metastatic potential to cells with
high metastatic potential is not solely attributable to the
inhibition of a single molecule but rather is a multistep
process involving many signal-transduction pathways.
In conclusion, our data demonstrate that melanoma cell
lines widely express both PDGFR-a and PDGFR-b tyrosine
kinases. Furthermore, the expression of these receptors
appears to correlate with the metastatic potential of the
melanoma cell lines tested. In mice bearing PDGFR-positive
xenografts, imatinib mesylate blocked phosphorylation of
these targets but had no effect on tumor growth, regardless
of whether these xenografts expressed c-Kit.
Materials and Methods
Cell culture The A375-p human melanoma cell line was estab-
lished in culture from a human lymph node metastasis (Kozlowski
et al, 1984). The highly metastatic A375SM cell line was
established from pooled lung metastases produced by A375-p
cells intravenously injected into nude mice (Li et al, 1989). The
TXM-13 melanoma cell line was established from a patient with a
melanoma brain metastasis at The University of Texas M.D.
Anderson Cancer Center. The MeWo melanoma, WM-266-4
melanoma, 3T3 fibroblast, and MG-63 osteosarcoma cell lines
were obtained from the American Type Culture Collection
(Manassas, VA). The SB-2 cell line was isolated from a primary
cutaneous lesion and was a gift of B. Giovanella (St. Joseph’s
Hospital Cancer Center Research Laboratory, Houston, TX). WM-
266-4 cells are highly malignant (Luca et al, 1995). In nude mice,
both MeWo and SB-2 cell lines are poorly tumorigenic and
nonmetastatic (Verschraegen et al, 1991; Luca et al, 1993; Singh
et al, 1995).
Cells were grown in 10% fetal calf serum and minimal essential
medium made complete by the addition of glutamine, HEPES,
streptomycin, nonessential amino acids, and multivitamins. Cells
were grown at 371C with 5% CO2. All cultures were free of
mycoplasma and pathogenic murine viruses.
Western blot analysis Melanoma cells were seeded at 1  106 in
100-mm tissue culture plates in 10 mL of complete minimal
essential medium. After overnight incubation, the cells were
washed with ice-cold phosphate-buffered saline (PBS) solution
and lyzed in 0.2 mL of lysis buffer (Cell Signaling Technologies,
Beverly, MA) at 41C for 30 min. Lysates were cleared by a 10-min
centrifugation at 10,000  g, and protein determination was
carried out according to standard methodology. Samples were
subjected to 7.5% PAGE analysis after they were boiled for 5 min in
sample buffer containing SDS. The separated proteins were
transferred to Immobilon-p membranes (Millipore, Bedford, MA)
and then blocked for 1 h in 1  Tris-buffered salineþ 0.1% Tween
20 containing 5% nonfat milk. The membrane was then incubated
with primary antibody in 1  Tris-buffered salineþ 0.1% Tween 20
overnight at 41C. Primary antibodies for PDGFR-a and PDGFR-b
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Equal loading of protein samples was confirmed by incubating
membranes with a primary antibody specific for actin (Santa Cruz
Biotechnology). Membranes were washed and then incubated for
1 h at room temperature with secondary antibody. Bound antibody
was detected using ECL reagent (Amersham Pharmacia, Piscat-
away, NJ).
Subcutaneous implantation and treatment of melanoma cells
in a nude mouse model Male athymic nude mice were purchased
from the animal production area of the NCI-Frederick Cancer
Research Facility (Frederick, MD) and maintained in specific-
pathogen-free-barrier animal facilities approved by the American
Association for Accreditation of Laboratory Animal Care (AAALAC).
They were used for experiments at 9 wk of age.
Cultured A375SM or MeWo cells were harvested at 80%
confluence for injection by a brief exposure to 0.25% trypsin
and 0.02% ethylenediaminetetraacetic acid. Trypsinization was
stopped after 2 min with addition of medium containing 10% fetal
calf serum, and the cells were washed once in serum-free medium
and resuspended in PBS. Only suspensions consisting of single
cells with 490% viability were used for the injections. The cells
were injected (1  106 cells/mouse) subcutaneously into the left
flank.
Three days after injection, the mice were randomly allocated to
one of two treatment groups: one group received PBS adminis-
tered by oral gavage three times weekly (control group) and the
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other, imatinib mesylate (100 mg/kg) by oral gavage three times
weekly (treatment group). Imatinib mesylate was provided by
Novartis Pharmaceuticals, Basel, Switzerland.
Tumor size was assessed once or twice weekly for 4 to 6
weeks. At each time point, mean tumor volume was compared
between the treatment group and the control group with a two-
tailed Student’s t test. The level of statistical significance was set at
po0.05.
Immunohistochemistry Frozen sections of the A375SM cell lines
grown orhotopically in nude mice treated with either imatinib
mesylate or PBS (control) were sectioned. The sections were
mounted on positively charged Plus slides (Fisher Scientific,
Pittsburgh, PA) and air-dried for 30 min. The sections were fixed
in cold acetone for 5 min followed by 1:1 acetone:chloroform (vol/
vol) for 5 min and then acetone for 5 min. The specimens were then
analyzed for the expression of PDGFR-a, PDGFR-b, and the
corresponding phosphorylated receptors. Samples were incu-
bated with protein-blocking solution containing 4% fish gel and
5% donkey serum in PBS for 20 min at room temperature. They
were then incubated at 41C for 18 h with a 1:100 dilution of the
primary antibody (rabbit polyclonal IgG to PDGFR-a (C-20), rabbit
polyclonal IgG to PDGFR-b (p-20), goat polyclonal IgG to
phosphorylated PDGFR-a (Tyr-720), and goat polyclonal IgG to
phosphorylated PDGFR-b (Tyr-1021), Santa Cruz Biotechnology,
Santa Cruz, CA). A positive reaction was visualized by incubating
the slides for 1 h with a 1:400 dilution of Alexa Fluor 488-
conjugated goat anti-rabbit or Alexa Fluor 488-conjugated rabbit
anti-goat (Molecular Probes, Eugene, OR) at room temperature,
avoiding exposure to light. Fluorescent bleaching was minimized
by covering the slides with 90% glycerol and 10% PBS.
Immunofluorescence microscopy was performed using a
20  objective and images were captured as previously described
(Bruns et al, 2000; Solorzano et al, 2001).
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